Natural killer (NK) cells are large granular lymphocytes involved in our defense against certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti-tumor responses based on signals from activating and inhibitory cell surface receptors. They also lyse target cells via antibody-dependent cellular cytotoxicity, a critical mode of action of several therapeutic antibodies used to treat cancer. A body of evidence shows that NK cells can exhibit potent anti-tumor activity against chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). However, disease-associated mechanisms often restrain the proper functions of endogenous NK cells, leading to inadequate tumor control and risk for disease progression. Although allogeneic NK cells can prevent leukemia relapse in certain settings of stem cell transplantation, not all patients are eligible for this type of therapy. Moreover, remissions induced by adoptively infused NK cells are only transient and require subsequent therapy to maintain durable responses. Hence, new strategies are needed to trigger full and durable anti-leukemia responses by NK cells in patients with myeloid malignancies. To achieve this, we need to better understand the interplay between the malignant cells, their microenvironment, and the NK cells. This review focuses on mechanisms that are involved in suppressing NK cells in patients with myeloid leukemia and MDS, and means to restore their full anti-tumor potential. It also discusses novel molecular targets and approaches, such as bi- and tri-specific antibodies and immune checkpoint inhibitors, to redirect and/or unleash the NK cells against the leukemic cells.
Keywords: NK cell dysfunction; NK cells; cancer immunotherapy; drug development; myeloid malignancy.
Copyright © 2019 Carlsten and Järås.
Haploidentical Natural Killer Cells Infused Before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I TrialDA Lee et al. Biol Blood Marrow Transplant 22 (7), 1290-1298. PMID 27090958. - Clinical TrialAllogeneic stem cell transplantation is an effective treatment for high-risk myeloid malignancies, but relapse remains the major post-transplantation cause of treatment f …
Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid LeukemiaN Hattori et al. Int J Mol Sci 20 (9). PMID 31027331. - ReviewThe most common cause of death in patients with acute myeloid leukemia (AML) who receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) is AML relapse. Th …
Natural Killer Cell (NK) Subsets and NK-like T-cell Populations in Acute Myeloid Leukemias and Myelodysplastic SyndromesN Aggarwal et al. Cytometry B Clin Cytom 90 (4), 349-57. PMID 26648320.The impact of the immune microenvironment on the behavior and therapeutic strategies for hematopoietic and lymphoid neoplasms is being increasingly recognized. Many funct …
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsN Dulphy et al. Front Immunol 7, 94. PMID 27014273. - ReviewAcute myeloid leukemia (AML) is a heterogeneous group of malignancies which incidence increases with age. The disease affects the differentiation of hematopoietic stem or …
In Vitro Culture With Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia PatientsB Sanchez-Correa et al. Front Immunol 8, 931. PMID 28824651.Despite recent progress in the therapeutic approach of malignant hemopathies, their prognoses remain frequently poor. Immunotherapy could open a new window of great inter …